Stefan Knapp

Stefan Knapp

SGC Frankfurt

Knapp

Biography

Prof Stefan Knapp studied Chemistry at the University of Marburg (Germany) and at the University of Illinois (USA). He did his PhD in protein crystallography at the Karolinska Institute in Stockholm (Sweden) (1996) and continued his career at the Karolinska Institute as a postdoctoral scientist (1996-1999). In 1999, he joined the Pharmacia Corporation as a principal research scientist in structural biology and biophysics. He left the company in 2004 to set up a research group at the Structural Genomics Consortium at Oxford University (SGC). From 2008 to 2015 he was a Professor of Structural Biology at the Nuffield Department of Clinical Medicine (NDM) at Oxford University (UK) and between 2012 and 2015 he was the Director for Chemical Biology at the Target Discovery Institute (TDI). He joined Frankfurt University (Germany) in 2015 as a Professor of Pharmaceutical Chemistry and the Buchmann Institute of Molecular Life Sciences. He remains associated to the SGC as a visiting Professor at Oxford and he is also adjunct Professor of the George Washington University. Since 2017 he is the CSO of the newly founded SGC node at the Goethe-University Frankfurt. His research interests are the rational design of selective inhibitors that target protein kinases as well as protein interactions modules that function as reader domains of the epigenetic code.

Research Areas

My laboratory is interested in understanding molecular mechanisms that regulate protein function of key signalling molecules and how these mechanisms can be utilized for the development of highly selective and potent inhibitors (chemical probes). As a basis for this work we have generated a comprehensive set of high resolution crystal structures that cover most members of the protein family of interest. We are particularly interested in protein interactions module of the bromodomain family that specifically recognize ε-N-lysine acetylation motifs, a key event in the reading process of epigenetic marks. This effort generated several highly selective chemical probes targeting bromodomains. A second research focus is on protein kinases. Our laboratory has solved a comprehensive set of crystal structure of this large protein family offering the opportunity to understand molecular mechanisms of their regulation and developing new strategies for their selective targeting. We developed for example a number of highly selective inhibitors by exploring unusual binding modes and allosteric binding sites. A particular focus of the laboratory is also to understand structural mechanisms leading to slow binding kinetics as part of the K4DD consortium.

2019

New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis.

Tazarki H, Zeinyeh W, Esvan YJ, Knapp S, Chatterjee D, Schröder M, Joerger AC, Khiari J, Josselin B, Baratte B, Bach S, Ruchaud S, Anizon F, Giraud F, Moreau P

Eur J Med Chem. 2019-1-26 . 166:304-317 .doi: 10.1016/j.ejmech.2019.01.052

PMID: 30731399

2018

An Activity-Based Probe Targeting Non-Catalytic, Highly Conserved Amino Acid Residues within Bromodomains.

D'Ascenzio M, Pugh KM, Konietzny R, Berridge G, Tallant C, Hashem S, Monteiro O, Thomas JR, Schirle M, Knapp S, Marsden B, Fedorov O, Bountra C, Kessler BM, Brennan PE

Angew. Chem. Int. Ed. Engl.. 2018-12-27 . .doi: 10.1002/anie.201807825

PMID: 30589164

Single-Molecule Protein Phosphorylation and Dephosphorylation by Nanopore Enzymology.

Harrington L, Alexander LT, Knapp S, Bayley H

ACS Nano. 2018-12-27 . .doi: 10.1021/acsnano.8b07697

PMID: 30588793

Furo[3,2-b]pyridine: A Privileged Scaffold for Highly Selective Kinase Inhibitors and Effective Modulators of the Hedgehog Pathway.

Němec V, Hylsová M, Maier L, Flegel J, Sievers S, Ziegler S, Schroeder M, Berger BT, Chaikuad A, Valčíková B, Uldrijan S, Drápela S, Souček K, Waldmann H, Knapp S, Paruch K

Angew. Chem. Int. Ed. Engl.. 2018-12-20 . .doi: 10.1002/anie.201810312

PMID: 30569600

A structure-based approach towards identification of inhibitory fragments for eleven-nineteen-leukemia protein (ENL).

Heidenreich D, Moustakim M, Schmidt J, Merk D, Brennan PE, Fedorov O, Chaikuad A, Knapp S

J. Med. Chem.. 2018-11-8 . .doi: 10.1021/acs.jmedchem.8b01457

PMID: 30407816

A Pseudo-Kinase Double Act.

Preuß F, Mathea S, Knapp S

Structure. 2018-11-6 . 26(11):1564 .doi: 10.1016/j.str.2018.10.019

PMID: 30403994

Binding Kinetics Survey of the Drugged Kinome.

Georgi V, Schiele F, Berger BT, Steffen A, Marin Zapata PA, Briem H, Menz S, Preuße C, Vasta JD, Robers MB, Brands M, Knapp S, Fernández-Montalván AE

J. Am. Chem. Soc.. 2018-10-26 . .doi: 10.1021/jacs.8b08048

PMID: 30362749

Structure of a glutamine donor mimicking inhibitory peptide shaped by the catalytic cleft of microbial transglutaminase.

Juettner NE, Schmelz S, Kraemer A, Knapp S, Becker B, Kolmar H, Scrima A, Fuchsbauer HL

FEBS J.. 2018-10-15 . .doi: 10.1111/febs.14678

PMID: 30318745

Discovery of an MLLT1/3 YEATS Domain Chemical Probe.

Moustakim M, Christott T, Monteiro OP, Bennett J, Giroud C, Ward J, Rogers CM, Smith P, Panagakou I, Saez LD, Felce SL, Gamble V, Gileadi C, Halidi N, Heidenreich D, Chaikuad A, Knapp S, Huber KVM, Farnie G, Heer J, Manevski N, Poda G, Al-Awar R, Dixon DJ, Fedorov O, Brennan P

Angew. Chem. Int. Ed. Engl.. 2018-10-5 . .doi: 10.1002/anie.201810617

PMID: 30288907

BRAF/MAPK and GSK3 signaling converges to control MITF nuclear export.

Ngeow KC, Friedrichsen HJ, Li L, Zeng Z, Andrews S, Volpon L, Brunsdon H, Berridge G, Picaud S, Fischer R, Lisle R, Knapp S, Filippakopoulos P, Knowles H, Steingrímsson E, Borden KLB, Patton EE, Goding CR

Proc. Natl. Acad. Sci. U.S.A.. 2018-8-27 . .doi: 10.1073/pnas.1810498115

PMID: 30150413